Skip to content

Abbott ABT Finished goods

Finished goods at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Haemonetics logo
HaemoneticsHAE
Artivion logo
ArtivionAORT
Boston Scientific logo
Boston ScientificBSX
DexCom logo
DexComDXCM

Other financials

Income statement

See full
Revenue$11.2B+7.8%
Gross profit$6.3B+6.5%
Operating income$1.3B-20.6%
Net income$1.1B-18.7%
EPS (diluted)$0.61-19.7%

Balance sheet

See full
Cash & equivalents$6.8B+4.1%
Total debt$34.0B+157%
Total equity$52.1B+6.7%
Total assets$110.43B+35.6%

Cash flow

See full
Operating cash flow$1.3B-7.2%
CapEx$399.0M-17.6%
Free cash flow$916.0M-1.8%

Valuation

See full
Market cap$158.05B-28.5%
Enterprise value$185.3B-19.1%
P/E25.2×+9.4×
P/S3.5×-1.6×

Profitability

See full
Gross margin56.3%+0.4pp
Operating margin17.1%+0.2pp
Net margin13.9%-18.0pp
FCF margin16.3%+0.6pp

Returns & leverage

See full
Return on equity12.4%-18.4pp
Debt / equity0.7×+0.4×
Current ratio1.4×-0.4×

Where this comes from

Reported directly by Abbott in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.

The official record: Abbott’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Abbott's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Abbott's finished goods?
Abbott (ABT) reported finished goods of $4.27B in Q1 2026.
How has Abbott's finished goods changed year-over-year?
Abbott's finished goods increased by 5.2% year-over-year, from $4.06B to $4.27B.
What is the long-term trend for Abbott's finished goods?
Over 5 years (2020 to 2025), Abbott's finished goods has grown at a 5.6% compound annual growth rate (CAGR), from $3.03B to $3.98B.